Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Sinopharm Dongfeng General Hospital, Hubei University of Medicine, 442008, Shiyan, China.
BMC Complement Med Ther. 2024 Apr 5;24(1):151. doi: 10.1186/s12906-024-04434-0.
Sodium tanshinone IIA sulfonate (STS) injection has been widely used as adjunctive therapy for pulmonary heart disease (PHD) in China. Nevertheless, the efficacy of STS injection has not been systematically evaluated so far. Hence, the efficacy of STS injection as adjunctive therapy for PHD was explored in this study.
Randomized controlled trials (RCTs) were screened from China Science and Technology Journal Database, China National Knowledge Infrastructure, Wanfang Database, PubMed, Sino-Med, Google Scholar, Medline, Chinese Biomedical Literature Database, Cochrane Library, Embase and Chinese Science Citation Database until 20 January 2024. Literature searching, data collection and quality assessment were independently performed by two investigators. The extracted data was analyzed with RevMan 5.4 and STATA 14.0. Basing on the methodological quality, dosage of STS injection, control group measures and intervention time, sensitivity analysis and subgroup analysis were performed.
19 RCTs with 1739 patients were included in this study. Results showed that as adjunctive therapy, STS injection combined with Western medicine showed better therapeutic efficacy than Western medicine alone for PHD by increasing the clinical effective rate (RR = 1.22; 95% CI, 1.17 to 1.27; p < 0.001), partial pressure of oxygen (MD = 10.16; 95% CI, 5.07 to 15.24; p < 0.001), left ventricular ejection fraction (MD = 8.66; 95% CI, 6.14 to 11.18; p < 0.001) and stroke volume (MD = 13.10; 95% CI, 11.83 to 14.38; p < 0.001), meanwhile decreasing the low shear blood viscosity (MD = -1.16; 95% CI, -1.57 to -0.74; p < 0.001), high shear blood viscosity (MD = -0.64; 95% CI, -0.86 to -0.42; p < 0.001), plasma viscosity (MD = -0.23; 95% CI, -0.30 to -0.17; p < 0.001), hematokrit (MD = -8.52; 95% CI, -11.06 to -5.98; p < 0.001), fibrinogen (MD = -0.62; 95% CI, -0.87 to -0.37; p < 0.001) and partial pressure of carbon dioxide (MD = -8.56; 95% CI, -12.09 to -5.02; p < 0.001).
STS injection as adjunctive therapy seemed to be more effective than Western medicine alone for PHD. However, due to low quality of the included RCTs, more well-designed RCTs were necessary to verify the efficacy of STS injection.
丹参酮ⅡA 磺酸钠(STS)注射液已在中国广泛用于肺心病(PHD)的辅助治疗。然而,STS 注射液的疗效尚未得到系统评价。因此,本研究旨在探讨 STS 注射液作为 PHD 辅助治疗的疗效。
从中国科技期刊数据库、中国知网、万方数据库、PubMed、SinoMed、Google Scholar、Medline、中国生物医学文献数据库、 Cochrane 图书馆、Embase 和中国科学引文数据库中筛选出随机对照试验(RCTs),检索时间截至 2024 年 1 月 20 日。两名研究者独立进行文献检索、数据收集和质量评估。使用 RevMan 5.4 和 STATA 14.0 对提取的数据进行分析。基于方法学质量、STS 注射液剂量、对照组措施和干预时间进行敏感性分析和亚组分析。
本研究纳入了 19 项 RCT,共 1739 名患者。结果表明,STS 注射液联合西药治疗 PHD 的临床有效率(RR=1.22;95%CI,1.17 至 1.27;p<0.001)、氧分压(MD=10.16;95%CI,5.07 至 15.24;p<0.001)、左心室射血分数(MD=8.66;95%CI,6.14 至 11.18;p<0.001)和每搏量(MD=13.10;95%CI,11.83 至 14.38;p<0.001)均优于西药组,同时降低了低切变血液黏度(MD=-1.16;95%CI,-1.57 至-0.74;p<0.001)、高切变血液黏度(MD=-0.64;95%CI,-0.86 至-0.42;p<0.001)、血浆黏度(MD=-0.23;95%CI,-0.30 至-0.17;p<0.001)、红细胞压积(MD=-8.52;95%CI,-11.06 至-5.98;p<0.001)、纤维蛋白原(MD=-0.62;95%CI,-0.87 至-0.37;p<0.001)和二氧化碳分压(MD=-8.56;95%CI,-12.09 至-5.02;p<0.001)。
STS 注射液联合西药治疗 PHD 似乎比单纯西药治疗更有效。然而,由于纳入的 RCT 质量较低,需要更多设计良好的 RCT 来验证 STS 注射液的疗效。